In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis's Research Experiment

Executive Summary

Against the trend, Novartis has dramatically increased its discovery infrastructure because, unlike most of its competitors, it believes it can cut R&D attrition. Drug research fails, its R&D execs believe, because it oversimplifies heterogeneous diseases. Instead, Novartis is testing drugs early in rare diseases that might be models of broader conditions. The proof-of-concept idea isn't new, but Novartis is exploiting it more extensively than anyone else, in virtually all new programs.
Advertisement

Related Content

Back To School: Big Pharmas Test New Models For Tapping Academia
With Genoptix, Novartis Continues Its Diagnostics Build-up
Novartis Follows Its Own Business Development Model into Molecular Diagnostics
Orphaned No Longer: Big Pharma Embraces Drugs for Niche Markets
Genzyme's Manufacturing Problems
Best of the Blog: IN VIVO, June 2008
Lilly's Chorus Experiment
CEO Interview: Novartis' Dan Vasella
The $100 Million IND
How Big Pharma is Tackling the R&D Problem

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV002764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel